09:10~10:00 Brca 突變的晚期乳癌及卵巢癌病人的治療考量
10:00~10:50 From triple-negative to Dx-positive breast cancer: Perspectives and experience with cancer immunotherapy for patients with metastatic triple negative disease
10:50~11:00 休息
11:00~11:50 Optimal 1L NSCLC treatment with Immunotherapy
11:50~13:00 午餐
13:00~13:50 Navigating HCC treatment decisions: What Do We Learn from Systemic Treatment
13:50~14:40 Evolving IO Combination Strategy in Frontline advanced NSCLC.
14:40~14:50 休息
14:50~15:40 A Good Start of Immunotherapy for Esophageal Cancer- Emerging Role and Future Perspectives.
15:40~16:00 Closing